The law firm of Kirby McInerney LLP reminds investors of the March 10, 2025, deadline to seek the role of lead plaintiff in a federal securities class ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been ...

the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies; (2) potential safety concerns with the Company's ongoing STRIDES clinical ...

BioAge Labs, Inc. (BIOA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeffrey ...

The decision follows observations of liver transaminitis without clinically significant symptoms, and without clear dose dependence, in some patients in the azelaprag arms of the STRIDES Phase 2 ...

Glucarpidase treatment significantly improves kidney recovery odds and reduces risks of neutropenia and transaminitis in MTX-AKI patients. The study utilized a target trial emulation framework to ...